Published 'success rates' for diabetes stem-cell therapy lack a standard definition and are not comparable across trials. Some report 'improvement' in glucose markers in 40–70% of participants, but assessments are usually unblinded and uncontrolled. Insulin-independence in Type 1 after stem cells is exceptional and unproven in rigorous trials; Type 2 shows variable, modest glucose reduction. Independent reviews highlight methodological weakness.
Two hundred thirty-six registered trials and 26 recruiting studies address stem-cell therapy in diabetes — the largest trial landscape among the conditions here. Small cohorts report modest improvements in insulin secretion and HbA1c, but quality is heterogeneous and controls are often absent. Some report temporary reductions in insulin requirement; durability beyond 12 months is poorly documented. No trial has produced insulin independence in Type 1, and sustained insulin-free control in Type 2 is rare.
我是候选人吗？ → · Diabetes (Type 1 & 2): full overview → · 糖尿病（1型和2型）成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估